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Abstract
Background: A new formulation of olanzapine available for terminally ill patients is needed. Rectal administration
using suppositories is an alternative for patients for whom administration via the oral route is not feasible. In the
present study, we prepared olanzapine suppositories, and confirmed using pharmaceutical tests. Furthermore, we
demonstrated the efficacy and safety of olanzapine suppositories in terminally ill patients.
Methods: We prepared olanzapine suppositories using bases consisting of different compositions of Witepsol H-15,
Witepsol S-55, and Witepsol E-75. The suppository release test was performed, and the olanzapine suppository with
the best dissolution rate was selected. The suppository was assessed using the content uniformity test, content test
in suppositories, hardness test, stability test, and clinical efficacy and safety.
Results: The dissolution rate at 360 min of olanzapine suppositories with Witepsol H-15 was the best (77.0 ± 3.3 %).
The suppositories prepared had a uniform weight (2.47 ± 0.02 g) and content (2.11 ± 0.07 mg). The power required
to break suppositories was 7.96 ± 0.55 kgf. When olanzapine suppositories were stored with protection from light,
their contents were maintained regardless of whether the temperature was at 4 °C or room temperature. The
numbers of patients administered 2.5 mg, 5 mg, and 10 mg of olanzapine suppositories were 4, 19, and 1. The
percentages of patients with delirium or nausea and vomiting cured with olanzapine suppositories were 82 and
57 %, respectively.
Conclusion: We suggest that olanzapine suppositories prepared in the hospital by pharmacists will improve the
quality of life of terminally ill patients.
Trial registration: UMIN000022172. May 2, 2016 retrospectively registered.
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Background
Delirium is a common and often serious medical com-
plication that occurs during the final 24 to 48 h of life in
85 to 90 % of terminally ill cancer patients [1, 2]. Morita
et al. reported that delirium not only occurs in the final
days of life, but also up to 29 days before death with a
median survival time of 10 days from the onset of delir-
ium [3]. Delirium is associated with increased morbidity
in terminally ill patients, and causes distress to patients,
family members, and staff [4–6]. Therefore, it is the
main contributing factor to a family’s inability to con-
tinue to care for patients in their home and a common
reason for admission to an inpatient hospice unit [7].
Palliative care is an approach that improves the quality
of life of patients and their families facing the challenges
associated with life-threatening illnesses.
Regarding pharmacological interventions, antipsychotic
medication is regarded as first-line pharmacotherapy for
delirium, with haloperidol, a typical antipsychotic, being
the most frequently administered drug [8]. Haloperidol
has fewer active metabolites and anticholinergic properties
and weaker sedative and hypotensive effects than other
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traditional antipsychotic agents [9]. However, its use has
been associated with the development of arrhythmia such
as torsade de pointes and extrapyramidal effects [8, 9].
Extrapyramidal symptoms are more likely to occur in the
elderly and strongly medically ill patients, who are also the
most susceptible to delirium [10]. Atypical antipsychotics
have a more favorable adverse effect profile due to their
decreased affinity for the D2 dopamine receptor, which
leads to weaker extrapyramidal effects [11]. Olanzapine is
an atypical antipsychotic agent of the thienobenzodiaze-
pine class. Atypical antipsychotics such as olanzapine have
recently been used to treat delirious patients due to their
equal effectiveness to and lower incidence of extrapy-
ramidal symptoms than haloperidol [10, 12]. Olanzapine
blocks multiple neurotransmitter receptors, including
dopaminergic (D1, D2, D3, and D4), serotonergic (5-hy-
droxytryptamine 2A [5-HT2A], 5-HT2C, 5-HT3, and 5-
HT6), adrenergic (α1), histaminic (H1), and muscarinic
(M1, M2, M3, and M4) receptors [13]. The affinity of olan-
zapine for multiple receptors has led to its identification
as an important agent in the treatment of delirium as well
as nausea and vomiting [13]. Several palliative care studies
have shown that olanzapine is useful and safe for the treat-
ment of delirium [13, 14]. Sedation is commonly used to
manage the symptoms of restlessness and agitation in the
terminal stage of illness [15, 16]. Sedation is a common
side effect in patients orally administered olanzapine, with
reported incident rates of 18.9–28.6 %. Thus, olanzapine
is commonly administered to terminally ill patients. How-
ever, an oral formulation is not appropriate because most
patients in the final days of life cannot take drugs orally.
Previous studies demonstrated that olanzapine was not
inferior to aprepitant in the prophylaxis of highly and
moderately emetogenic chemotherapy and that it in-
creased the rate of a complete response when added to a
combination of a 5-HT3 antagonist, aprepitant, and dexa-
methasone [17]. However, an oral formulation is not ap-
propriate because the ingestion of an oral drug in patients
with vomiting or severe nausea may induce emesis.
Thus, a new formulation of olanzapine available for
terminally ill patients is needed. Rectal administration
using suppositories is an alternative for patients for
whom administration via the oral route is not feasible.
Rectal administration is more advantageous than intra-
venous administration because aseptic handling is not
required and patients may administer the drugs in their
own homes. Therefore, the rectal administration of an
olanzapine suppository appears to be clinically useful for
the treatment of terminally ill patients with delirium,
vomiting, or nausea. In the present study, we prepared
olanzapine suppositories using bases consisting of different
compositions of Witepsol H-15, Witepsol S-55, and
Witepsol E-75. The suppository release test was performed,
and the olanzapine suppository with the best dissolution
rate was selected. The suppository was assessed using the
content uniformity test, content test in suppositories, hard-
ness test, stability test, and clinical efficacy.
Methods
Materials
Zyprexa® tablets 2.5 mg (containing 2.5 mg olanzapine)
were purchased from Eli Lilly Japan K. K. (Hyogo, Japan).
Witepsol H-15, S-5, and E-75 suppository molds (2.25 cm3)
were purchased from Maruishi Pharmaceutical Co., Ltd.
(Osaka, Japan). Olanzapine, perchloric acid (60 %), 10 %
ammonia solution, dipotassium hydrogen phosphate, and
1 mol/L potassium hydroxide solution were purchased
from Wako Pure Chemical Industries, Ltd. (Osaka, Japan).
Tetramethylammonium perchlorate was purchased from
Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). Potas-
sium dihydrogen phosphate and acetonitrile were pur-
chased from Nacalai Tesque, Inc. (Kyoto, Japan).
Preparation of the olanzapine suppository
Suppository bases consisting of different compositions of
H-15, S-55, and E-75 (Table 1) were completely melted
at 40 °C. Zyprexa® tablets were crushed in a mortar and
sifted through a 50 mesh sieve. The crushed powder was
added to the melted base and dispersed uniformly. The
mixture was poured into a suppository mold and left at
room temperature for 24 h to solidify.
Suppository release test
The suppository release test was performed according to
the reciprocating dialysis tube method with tapping
using the dissolution apparatus HZ-21D (Miyamoto
Riken Ind. Co., Ltd., Osaka, Japan) [18]. Phosphate buffer
(pH 7.0) was used as the testing medium. The volume of
the testing medium was 900 mL, and the test was per-
formed at 37 °C. The dialysis membrane (size 27, length
21 cm) was soaked in purified water and rinsed before
use. The arm of the apparatus moved up and down
automatically at a constant speed (30 number/min). Four
hundred microliters of the buffer was sampled at each
time point (30, 60, 90, 120, 150, 180, 210, 240, 270, 300,
330, and 360 min), and 400 μL of fresh buffer was added
Table 1 Composition of different Witepsol suppositories
Component (%) H-15 S-55 E-75
H-15 100 - -
H-15:S-55 = 1:1 50 50 -
H-15:S-55 = 2:1 67 33 -
H-15:S-55 = 1:2 33 67 -
S-55 - 100 -
S-55:E-75 = 1:1 - 50 50
E-75 - - 100
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to maintain the same volume. Samples (n = 6) were
analyzed using high-performance liquid chromatography
(HPLC).
Measurement of olanzapine concentrations
Olanzapine concentrations were measured by HPLC
with minor modifications to the methods described by
Raggi et al. [19]. The analytical column was ZORBAX
Eclipse Plus C8, 5 μm, 150 × 4.6 mm, the UV wave-
length for olanzapine was 260 nm, and the mobile
phase consisted of 17 mM tetramethylammonium per-
chlorate (pH 3.1):acetonitrile = 77:23. The flow rate was
0.4 mL/min.
Content uniformity test
Ten olanzapine suppositories were selected randomly
and their weights and olanzapine contents determined.
A suppository was placed into a flask, 1000 mL purified
water (65 °C) was added, and it was completely melted.
The suspension obtained was stirred and the flask was
cooled on ice to solidify the base. After cooling, the sus-
pension was centrifuged at 3,500 rpm at 4 °C for 5 min,
and the supernatant was filtered through filter paper
(0.45 μm). The filtrate was analyzed by HPLC.
Content test in suppositories
Three olanzapine suppositories were randomly selected
and cut in half crosswise. The bulbous head and tail
parts were obtained. Their contents were determined in
the same manner as the content uniformity test.
Hardness test
Fifteen olanzapine suppositories were randomly selected
and hardness was determined using a hardness tester
(EZ-test: Shimadzu Co., Kyoto, Japan).
Stability test
Prepared olanzapine suppositories were stored under 3
conditions for 1, 2, 3, 4, 6, 8, 12, and 24 weeks: (i) at 4 °C
protected from light, (ii) at room temperature (25–30 °C)
protected from light, and (iii) at room temperature with-
out protection from light. After storage, the contents of
olanzapine suppositories were determined in the same
manner as the content uniformity test (n = 3).
Clinical application of olanzapine suppositories
This study was approved by the Ethics Review Board of
Shonan Central Hospital (#0182). Written informed
consent was obtained from 24 adult patients who were ad-
ministered olanzapine suppositories between July 2014
and April 2015 at Shonan Central Hospital. When the
administration route was changed from oral to rectal,
the same dose was used. When olanzapine suppository
was newly administered in terminally ill patients, a dose of
2.5 mg or 5.0 mg was determined by physicians. Re-
sponses to olanzapine therapy were evaluated based on
clinical assessments by physicians. Information about the
side effects such as sleepiness, mucous membrane damage
caused by local irritation and diarrhea was extracted from
the electronic medical records of each patient.
Statistical analysis
Data are presented as the mean ± standard deviation
(S.D.). Significance was analyzed using Dunnett’s test for
multiple comparisons, and the Student’s t-test for two-
group comparisons. Differences at P < 0.05 were consid-
ered significant. All statistical analyses were conducted
using Microsoft Office Excel 2010 with the add-in soft-
ware Statcel 3 (OMS, Inc., Hyogo, Japan).
Results
Suppository release test
The dissolution profiles of olanzapine suppositories
manufactured using different compositions of H-15,
S-55, and H-15 (Table 1) are shown in Fig. 1. The 50 %
olanzapine release time of olanzapine suppositories with
H-15, H-15:S-55 = 1:1, H-15:S-55 = 2:1, H-15:S-55 = 1:2,
H-15:S-55 = 1:2, and S-55:E-75 = 1:1 as the bases were
150, 150, 165, 195, 250, and 250 min, respectively. The
suppository with E-75 was not released by 360 min. The
dissolution rates at 360 min of olanzapine suppositories
with H-15, H-15:S-55 = 1:1, H-15:S-55 = 2:1, H-15:S-55 =
1:2, H-15:S-55 = 1:2, S-55:E-75 = 1:1, and E-75 were 77.0
± 3.3 %, 76.9 ± 3.4 %, 73.3 ± 4.2 %, 69.7 ± 2.7 %, 54.5 ±
2.1 %, 60.7 ± 4.7 %, and 44.9 ± 4.9 %, respectively. The
dissolution rates of suppositories with bases consisting of
H-15 or H-15:S-55 = 1:1 were the best. Furthermore, since
only H-15 was easier to prepare than the mixture of H-15
and S-55, Witepsol H-15 was selected as the base.
Content uniformity test, content test in suppositories,
and hardness test
The weight and content of olanzapine suppositories
were 2.47 ± 0.02 g and 2.11 ± 0.07 mg, respectively. Con-
tent uniformity was checked using the content uniform-
ity test laid out in the Japanese Pharmacopoeia (JP) 16th
edition, and was confirmed to meet the JP criteria. The
olanzapine concentrations of the bulbous head part and
tail part were 1.35 ± 0.08 and 1.10 ± 0.07 mg/g, respect-
ively. The power required to break suppositories was
7.96 ± 0.55 kgf.
Stability test
When olanzapine suppositories were stored at room
temperature without protection from light, their con-
tents significantly decreased (Fig. 2). Their contents de-
creased to 89 % in 1 week. In contrast, when olanzapine
suppositories were stored with protection from light,
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their contents were maintained regardless of whether the
temperature was at 4 °C or room temperature.
Clinical effects
Patient characteristics are shown in Table 2. Fifteen men
and 9 women, with a median age of 78 years, were eval-
uated in the present study. All patients had oral feeding
difficulties. The numbers of patients changed from oral
olanzapine and other oral atypical antipsychotics to
olanzapine suppositories were 5 and 8, respectively.
Eleven patients used olanzapine suppositories as a treat-
ment for delirium or nausea and vomiting at the time of
oral feeding difficulties. The numbers of patients adminis-
tered 2.5 mg, 5 mg, and 10 mg of olanzapine suppositories
were 4, 19, and 1. The median duration of the treatment
was 11 days (Table 2). Table 3 shows the therapeutic effi-
cacy of olanzapine suppositories in patients with delirium
or nausea and vomiting. The percentages of patients with
Fig. 1 Effects of suppository bases on the release of olanzapine from suppositories. Each value represents the mean ± S.D. (n = 6)
Fig. 2 Stability of olanzapine suppositories under various storage conditions. Each value represents the mean ± S.D. (n = 3). **P < 0.01 significantly
different from day 1 in the room temperature group
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delirium or nausea and vomiting cured with olanzapine
suppositories were 82 and 57 %, respectively. The reasons
for the discontinuation of olanzapine suppositories were
death (15 patients), a decreased level of consciousness
(7 patients), and side effects (2 patients: sleepiness).
There were no patients with mucous membrane dam-
age caused by local irritation and diarrhea.
Discussion
Suppositories need to show consistent release charac-
teristics under the temperature range of the rectum
(36.5–37.5 °C). Since olanzapine is a lipophilic drug, we
selected Witepsol as the lipophilic base most widely used
in clinical practice. The suppository release test was
performed according to the reciprocating dialysis tube
method with tapping. The dialysis tube method better
simulates physiological conditions given that there is only
a small amount of fluid in the rectum and showed high
reproducibility and an in vitro-in vivo correlation in rab-
bits [18, 20]. As shown in Fig. 1, the dissolution rate at
360 min of the olanzapine suppository with H-15 was
77.0 ± 3.3 %. But, the suppository with E-75 was not re-
leased by 360 min. The melting points of H-15 and S-55
were 33.5–35.5 °C. On the other hand, the melting point
of E-75 was 37–39 °C. We considered the suppository
with E-75 to be difficult to dissolve at 37 °C. It keeps the
degree of viscosity as low as possible in order to release
the drug from the suppository [21]. Since the viscosity of
H-15 was lower than that of S-55, olanzapine with H-15
was released at a more rapid rate than S-55 (Fig. 1).
The olanzapine concentrations of the bulbous head
part and tail part were different in this study. Thus,
dividing the suppository is not recommended. When we
prepared olanzapine suppositories, the drug sometimes
settled in the bulbous head part. Further studies are
needed in order to achieve uniform concentrations in
both parts.
A previous study reported that the power required to
break original and generic acetaminophen suppositories
was 5.3–8.9 kgf [22]. The hardness of the current sup-
positories was similar to that of other suppositories.
Although Zyprexa® tablets remained stable at room
temperature when exposed to light, fine granules did
not. When olanzapine suppositories were stored at room
temperature without protection from light, their con-
tents significantly decreased (Fig. 2). Therefore, olanza-
pine suppositories need to be stored with protection
from light in order to avoid a decrease in their contents;
under these conditions, their contents were confirmed
to remain stable for 24 weeks.
In previous studies, 64.7–82.4 % of patients orally
administered olanzapine achieved the resolution of
delirium [23, 24]. In palliative care, olanzapine has been
shown to control or reduce the intensity of nausea and
vomiting [17]. These findings are consistent with the re-
sults of the present study (Table 3). Therefore, we herein
demonstrated the efficacy of olanzapine suppositories.
On the other hand, only 2 patients given suppositories
discontinued due to side effects (sleepiness). Blood sam-
pling is not routinely performed in terminally ill pa-
tients; therefore we could not check blood glucose
concentrations, liver and kidney function tests, etc. with
blood tests.
This study has some limitations. This was an un-
controlled study without comparative data in non-
administration group. Additionally, the results of this
study were obtained in a small number of patients. There-
fore, further studies such as prospective randomized
contolled study involving a large number of patients are
needed to confirm the current findings. We were unable
to analyze pharmacokinetics in patients administered
olanzapine suppositories. When olanzapine was admi-
nistered orally to patients at doses of 5 ± 2.5 and 10 ±
2.5 mg/day, mean blood concentrations were 10.3 ± 8.0
and 18.4 ± 12.1 ng/mL, respectively [25]. Olanzapine
blood concentrations are very low. We were unable to em-
ploy HPLC with ultraviolet. Liquid chromatography
Table 2 Characteristics of 24 patients included in the present
study
Characteristics Number or median ± S.D. (range)
Sex
Male:female 15:9
Age (years) 78 ± 10 (59–89)
Treatment duration (days) 11 ± 18 (1–73)
Underlying disease
Lung cancer 6
Large bowel cancer 3
Pancreatic cancer 2









Table 3 Therapeutic efficacy of olanzapine suppositories in
patients with delirium or nausea and vomiting
Daily dose (g) Success Failure Cure rate (%)
Delirium 18 4 82
Nausea and vomiting 4 3 57
Matsumoto et al. Journal of Pharmaceutical Health Care and Sciences  (2016) 2:20 Page 5 of 7
tandem mass spectrometry (LC-MS/MS) is needed in
order to measure olanzapine blood concentrations [26].
Another reason is the lower frequency of blood sampling
in terminally ill patients with cancer. Therefore, we were
unable to obtain blood concentrations. Previous studies
reported that the mechanism underlying drug absorption
from the rectum may not differ from that in the upper
part of the gastrointestinal tract [27, 28]. The hepatic first-
pass elimination of high clearance drugs is partly avoided
with rectal administration. After oral administration, 85 %
of olanzapine is readily absorbed; however, due to high
first-pass hepatic metabolism, its oral bioavailability is only
60 % [29]. Thus, patients given suppositories may have
higher blood concentrations than those receiving drugs
via an oral route.
We considered that suppositories would be able to be
prepared more easily by the use of solutions of risperi-
done. Furthermore, the clinical response rates to delir-
ium did not differ significantly between olanzapine and
risperidone [23, 24]. But, olanzapine-induced sedation
occurred more frequently than risperidone [23]. So, we
selected olanzapine, because sedation is commonly used
to manage the symptoms of restlessness and agitation in
the terminal stage of illness [15, 16].
Conclusion
We prepared olanzapine suppositories, and demonstrated
the efficacy in terminally ill patients. Rectal administration
using suppositories is an alternative for patients for whom
administration via the oral route is not feasible. We sug-
gest that olanzapine suppositories prepared in the hospital
by pharmacists will improve the quality of life of termin-
ally ill patients. But, we were unable to analyze pharmaco-
kinetics in patients administered olanzapine suppositories.
Although the number of blood sampling should be the
minimum for terminally ill patients, olanzapine blood
concentrations will need to be measured with LC-MS/MS
to assure the safety in the future.
Abbreviations
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